Pancreatic cancer: personalized medicine is linked to better survival

  • Lancet Oncol

  • curated by Jim Kling
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • An analysis of the Know Your Tumor program shows better survival when patients with actionable mutations receive matched therapies.

Why this matters

  • The study found an associated survival benefit of more than a year, longer than the time observed with any other therapeutic modality.

Study design

  • Retrospective analysis of the Know Your Tumor Program (N=1082; pancreatic ductal adenocarcinoma, adenosquamous carcinoma, acinar cell carcinoma).
  • Funding: Pancreatic Cancer Action Network, Perthera.

Key results

  • 26% of samples had an actionable molecular alteration.
  • Outcomes were available for 677 patients.
  • 189 had actionable molecular alterations.
  • Median follow-up, 383 (interquartile range, 214-588) days.
  • 46 of 189 patients with actionable molecular alterations received targeted therapy.
  • Patients with actionable molecular alterations had longer median OS with matched vs unmatched therapy:
    • 2.58 vs 1.51 years (HR, 0.42; P=.0004). 
  • Matched therapy also had significantly longer overall survival in patients with actionable molecular alterations than in patients without:
    • 2.58 years vs 1.32 years (HR, 0.34, p<.0001>
  • Median OS did not differ significantly between patients who received unmatched therapies with and those without actionable molecular alterations.

Limitations

  • Retrospective analysis.
  • Small sample sizes.